Treatment of chronic hepatitis D (HDV) with anti-HBsAg antibodies

JP2026519024APending Publication Date: 2026-06-11BLUEJAY THERAPEUTICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Applications
Current Assignee / Owner: BLUEJAY THERAPEUTICS INC
Filing Date: 2024-05-30
Publication Date: 2026-06-11

Application Information

Patent Timeline

30 May 2024

Application

11 Jun 2026

Publication

JP2026519024A

IPC: A61K39/395; A61P1/16; A61P29/00; A61P31/14; A61K9/08; C07K16/082; C07K16/46; C07K19/00; G01N33/576; G01N33/532; C07K16/18

CPC: G01N33/56983; A61P31/20; A61K2039/505; C07K16/10; C07K2317/76; C07K16/082; C07K2317/565; C07K2317/41

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure 2026519024000001_ABST

Patent Text Reader

Abstract

The present invention relates to anti-HBsAg antibodies, antibody fragments thereof, and their uses for the prevention and treatment of hepatitis D virus infection and related diseases. Also provided is a method for neutralizing hepatitis D virus infection, comprising administering an effective amount of the antibody or its antigen-binding fragment to a patient in need by injection or infusion.

Need to check novelty before this filing date? Find Prior Art